Anzeige
Mehr »
Freitag, 06.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40QAB | ISIN: US92829J2033 | Ticker-Symbol:
NASDAQ
05.06.25 | 21:57
4,880 US-Dollar
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
DOGWOOD THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
DOGWOOD THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur DOGWOOD THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
09.05.Dogwood Therapeutics, Inc. - 10-Q, Quarterly Report1
08.05.Virios Therapeutics Non-GAAP EPS of -$8.451
DOGWOOD THERAPEUTICS Aktie jetzt für 0€ handeln
08.05.Dogwood Therapeutics, Inc. - 8-K, Current Report1
01.05.D.Boral Capital: Dogwood Therapeutics, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference310Alpharetta, Georgia--(Newsfile Corp. - May 1, 2025) - Dogwood Therapeutics, Inc. (NASDAQ: DWTX), today announced its participation in the D. Boral Capital Inaugural Global Conference, taking place...
► Artikel lesen
21.04.Dogwood Therapeutics Stock Jumps 51%8
11.04.Dogwood Therapeutics erfüllt wieder die NASDAQ-Anforderungen3
11.04.Dogwood Therapeutics, Inc. Receives Nasdaq Confirmation of Compliance171ATLANTA, April 11, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the "Company"), a development-stage biopharmaceutical company focused on developing new medicines to treat pain...
► Artikel lesen
03.04.Dogwood Therapeutics erlangt NASDAQ-Konformität wieder10
03.04.Dogwood Therapeutics regains compliance with Nasdaq4
03.04.Dogwood Therapeutics regains Nasdaq compliance1
03.04.Dogwood Therapeutics, Inc. Regains Nasdaq Compliance188ATLANTA, April 03, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the "Company"), a development-stage biopharmaceutical company focused on developing new medicines to treat pain...
► Artikel lesen
31.03.Dogwood Therapeutics, Inc. - 10-K, Annual Report1
31.03.Dogwood Therapeutics, Inc. - 8-K, Current Report2
31.03.Dogwood Therapeutics, Inc.: Dogwood Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results99-Dogwood Therapeutics, Inc. commenced dosing of patients in the Halneuron® Chemotherapy Induced Neuropathic Pain ("CINP") Phase 2b Trial - - Halneuron® CINP P2b study interim data readout is expected...
► Artikel lesen
18.03.Dogwood Therapeutics begins Phase 2b trial for neuropathic pain2
18.03.Dogwood Therapeutics startet Phase-2b-Studie für neuropathische Schmerzen18
18.03.Dogwood Therapeutics, Inc.: Dogwood Therapeutics Announces Dosing of First Patient in Phase 2b Trial Evaluating Halneuron in Patients with Chemotherapy-Induced Neuropathic Pain326ATLANTA, March 18, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) ("Dogwood" or the "Company"), a development-stage biopharmaceutical company focused on advancing first-in-class...
► Artikel lesen
13.03.Dogwood Therapeutics announces pricing of $4.8 million offering2
13.03.Dogwood Therapeutics, Inc. Announces Pricing of $4.8 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules1
12.03.Dogwood Therapeutics, Inc. - 8-K, Current Report1
Weiter >>
30 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1